Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-ANG3 · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| ARO-ANG3 50 mg | EXPERIMENTAL | Two doses of ARO-ANG3 by subcutaneous (sc) injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. |
| ARO-ANG3 100 mg | EXPERIMENTAL | Two doses of ARO-ANG3 bysc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. |
| ARO-ANG3 200 mg | EXPERIMENTAL | Two doses of ARO-ANG3 by sc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. |
| Placebo | PLACEBO_COMPARATOR | Calculated volume to match active treatment by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. |
| ARO-ANG3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARO-ANG3 | DRUG | ARO-ANG3 Injection |
| Placebo | DRUG | Sterile Normal Saline (0.9% NaCl) |
| sterile normal saline (0.9% NaCl) | DRUG | calculated volume to match active treatment |
Inclusion Criteria: * Based on medical history, evidence of triglycerides (TG) ≥ 150 mg/dL but ≤ 499 mg/dL * Fasting levels at Screening of LDL-C ≥ 70 mg/dL OR non-HDL-C ≥ 100 mg/dL after at least 4 weeks of stable diet and stable optimal statin therapy * Mean fasting TG ≥ 150 mg/dL and ≤ 499 mg/dL...
ARO-ANG3 is an investigational drug being studied for the treatment of dyslipidemias, including mixed dyslipidemia, familial hypercholesterolemia, and hypertriglyceridemia. It is being developed by Arrowhead Pharmaceuticals, Inc. (ARWR) and is currently in clinical development, with studies conducted in healthy volunteers and in patients with dyslipidemia.
ARO-ANG3 is a small molecule that targets angiopoietin-like 3 (ANGPTL3), a protein involved in lipid metabolism. By inhibiting ANGPTL3, ARO-ANG3 aims to reduce lipid levels in the blood, which may help treat dyslipidemias. This mechanism is being evaluated in clinical trials for conditions such as mixed dyslipidemia and familial hypercholesterolemia.
ARO-ANG3 is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker ARWR. The company is conducting clinical trials to evaluate the safety and efficacy of ARO-ANG3 in patients with dyslipidemias.
ARO-ANG3 has completed Phase 1 and Phase 2 clinical trials. It is an investigational drug and has not been approved by the FDA. The development program includes studies in healthy volunteers and in patients with dyslipidemias, with the most advanced trial being a Phase 2 study in adults with mixed dyslipidemia.
ARO-ANG3 has been studied in two completed clinical trials. NCT03747224 was a Phase 1 study in healthy volunteers and dyslipidemic patients with conditions such as familial hypercholesterolemia and hypertriglyceridemia. NCT04832971 was a Phase 2 study in adults with mixed dyslipidemia, enrolling 204 participants across the United States, Australia, Canada, and New Zealand.
ARO-ANG3 is also known by its chemical name, and it is a distinct investigational agent developed by Arrowhead Pharmaceuticals. It is not the same as other approved lipid-lowering drugs, as it specifically targets angiopoietin-like 3 (ANGPTL3) through a small molecule approach, which is different from statins or PCSK9 inhibitors.